Genmab — August 2019
-
-
-
God morgen
-
-
XmAb14045 (CD123 x CD3): Clinical sites participating in the Phase 1 study in patients with relapsed/refectory acute myeloid leukemia have resumed enrollment, and in early July the first patient was dosed under the study's amended protocol. Amendments to the protocol included guidance on the monitoring and clinical management of cytokine release syndrome.
-
-
Børsen's artikel går lidt mere i retning af Darzalex bashing synes jeg, men jeg ved slet ikke nok om det til at bedømme om de har ret i noget af det. Claus Henrik Johansen fra Danske Bank peger på nogle negative ting ved Darzalex.
-
Copy/paste af artiklen er nok ikke lovligt så det vil jeg undlade.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind